Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

Taimur Sher; Kena C. Miller; David Lawrence; Amy Whitworth; Francisco Hernandez-Ilizaliturri; Myron S. Czuczman; Austin Miller; William Lawrence; Syed Ali Bilgrami; Raman Sood; Margaret T. Wood; Annemarie W. Block; Kelvin Lee; Asher Alban Chanan-Khan

doi:10.3109/10428190903406806

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

Taimur Sher, Kena C. Miller, David Lawrence, Amy Whitworth, Francisco Hernandez-Ilizaliturri, Myron S. Czuczman, Austin Miller, William Lawrence, Syed Ali Bilgrami, Raman Sood, Margaret T. Wood, Annemarie W. Block, Kelvin Lee, Asher Alban Chanan-Khan

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Article › peer-review

77 Scopus citations

Abstract

Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

Original language	English (US)
Pages (from-to)	85-88
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	51
Issue number	1
DOIs	https://doi.org/10.3109/10428190903406806
State	Published - Jan 2010

Keywords

Chronic lymphocytic leukemia
Fludarabine-refractory
High-risk cytogenetics
Lenalidomide

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428190903406806

Cite this

Sher, T., Miller, K. C., Lawrence, D., Whitworth, A., Hernandez-Ilizaliturri, F., Czuczman, M. S., Miller, A., Lawrence, W., Bilgrami, S. A., Sood, R., Wood, M. T., Block, A. W., Lee, K., & Chanan-Khan, A. A. (2010). Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia and Lymphoma, 51(1), 85-88. https://doi.org/10.3109/10428190903406806

Sher, T, Miller, KC, Lawrence, D, Whitworth, A, Hernandez-Ilizaliturri, F, Czuczman, MS, Miller, A, Lawrence, W, Bilgrami, SA, Sood, R, Wood, MT, Block, AW, Lee, K & Chanan-Khan, AA 2010, 'Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics', Leukemia and Lymphoma, vol. 51, no. 1, pp. 85-88. https://doi.org/10.3109/10428190903406806

@article{7dea72a981a3474c9d6951bc46af16b4,

title = "Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics",

abstract = "Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.",

keywords = "Chronic lymphocytic leukemia, Fludarabine-refractory, High-risk cytogenetics, Lenalidomide",

author = "Taimur Sher and Miller, {Kena C.} and David Lawrence and Amy Whitworth and Francisco Hernandez-Ilizaliturri and Czuczman, {Myron S.} and Austin Miller and William Lawrence and Bilgrami, {Syed Ali} and Raman Sood and Wood, {Margaret T.} and Block, {Annemarie W.} and Kelvin Lee and Chanan-Khan, {Asher Alban}",

note = "Funding Information: A. C. K. is a Leukemia and Lymphoma Society Scholar. This research is partly funded by the Leukemia and Lymphoma Society (A. C. K.). Wei Tan and Dr. Greg Wilding worked on additional statistical analysis. K. Miller served as a member of Speaker{\textquoteright}s bureau Celgene and Millennium, M. Czuczman was a member of Celgene Advisory Board, R. Sood served as a member in Stocks in Celgene Corporation, and A. Chanan-Khan was a member of Celgene Advisory Board, speaker{\textquoteright}s Bureau of Celgene.",

year = "2010",

month = jan,

doi = "10.3109/10428190903406806",

language = "English (US)",

volume = "51",

pages = "85--88",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

AU - Sher, Taimur

AU - Miller, Kena C.

AU - Lawrence, David

AU - Whitworth, Amy

AU - Hernandez-Ilizaliturri, Francisco

AU - Czuczman, Myron S.

AU - Miller, Austin

AU - Lawrence, William

AU - Bilgrami, Syed Ali

AU - Sood, Raman

AU - Wood, Margaret T.

AU - Block, Annemarie W.

AU - Lee, Kelvin

AU - Chanan-Khan, Asher Alban

N1 - Funding Information: A. C. K. is a Leukemia and Lymphoma Society Scholar. This research is partly funded by the Leukemia and Lymphoma Society (A. C. K.). Wei Tan and Dr. Greg Wilding worked on additional statistical analysis. K. Miller served as a member of Speaker’s bureau Celgene and Millennium, M. Czuczman was a member of Celgene Advisory Board, R. Sood served as a member in Stocks in Celgene Corporation, and A. Chanan-Khan was a member of Celgene Advisory Board, speaker’s Bureau of Celgene.

PY - 2010/1

Y1 - 2010/1

N2 - Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

AB - Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than emonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.

KW - Chronic lymphocytic leukemia

KW - Fludarabine-refractory

KW - High-risk cytogenetics

KW - Lenalidomide

UR - http://www.scopus.com/inward/record.url?scp=74949083498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949083498&partnerID=8YFLogxK

U2 - 10.3109/10428190903406806

DO - 10.3109/10428190903406806

M3 - Article

C2 - 20055660

AN - SCOPUS:74949083498

SN - 1042-8194

VL - 51

SP - 85

EP - 88

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this